Huntington's Disease: Mouse Study Finds a Second Route

What is Huntington’s disease?

Huntington’s disease is a progressive inherited neurodegenerative disorder. It affects movement, thinking, behaviour and mental health. A mutation in the HTT gene causes the condition.

The mutation contains an expanded cytosine-adenine-guanine, or CAG, sequence.

The gene supplies instructions for the huntingtin protein. An abnormally long repeat produces an expanded polyglutamine region within that protein. Symptoms often begin in adulthood, although timing varies widely.

Movement problems may include involuntary jerking, poor coordination and difficulty swallowing. Cognitive decline and psychiatric symptoms can appear before obvious movement changes.

Care therefore requires neurological, psychiatric and social support. The disease follows autosomal-dominant inheritance. Each child of an affected parent has a 50 per cent chance of inheriting the variant.

Predictive genetic testing has major emotional and family consequences. It should be accompanied by informed consent and specialist counselling.

What the new research found

The open-access study appeared in Nature Communications on 6 May 2026. Lawrence Berkeley National Laboratory scientists led the work. Researchers studied male mice carrying about 150 CAG repeats.

This model develops repeat expansion and disease-like changes with age. CAG sequences can lengthen further inside some body cells. This process is called somatic expansion.

The team also examined double-strand breaks, where both strands of DNA become severed. Cells normally repair such dangerous lesions. The researchers found that mutant huntingtin impaired a repair route called non-homologous end joining.

Genome-wide breaks then accumulated over time. Somatic expansion and double-strand breaks occurred together but followed separable mechanisms. Suppressing breaks reversed neuropathology despite continuing expansion in these mice.

Why the result matters

Much therapeutic research focuses on lowering mutant huntingtin or limiting CAG expansion. The study suggests DNA-break repair may offer another target. That possibility could explain why repeat expansion alone does not predict every damaged neuron.

It may also support combination approaches. Translation will be difficult. DNA-repair pathways protect every cell, so broad manipulation could produce serious unintended effects.

Researchers must reproduce the findings in other models and human tissue. They also need safe targets, measurable biomarkers and long-term toxicity data.

No treatment presently cures Huntington’s disease. Medicines and multidisciplinary care can manage some movement, mood and practical problems.

Conclusion

The mouse findings widen understanding of neuronal injury. Their promise lies in guiding rigorous research, not offering premature clinical hope.